24,000 Shares in Bionano Genomics, Inc. (NASDAQ:BNGO) Acquired by Carret Asset Management LLC
Carret Asset Management LLC purchased a new position in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 24,000 shares of the company’s stock, valued at approximately $74,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of BNGO. JPMorgan Chase & Co. bought a new stake in shares of Bionano Genomics in the 3rd quarter worth approximately $40,000. Virtu Financial LLC bought a new stake in shares of Bionano Genomics during the third quarter valued at approximately $164,000. Archford Capital Strategies LLC purchased a new position in Bionano Genomics during the fourth quarter valued at $328,000. Creative Planning purchased a new position in Bionano Genomics during the fourth quarter valued at $139,000. Finally, Victory Capital Management Inc. raised its stake in Bionano Genomics by 16.6% during the fourth quarter. Victory Capital Management Inc. now owns 24,893 shares of the company’s stock valued at $77,000 after buying an additional 3,539 shares during the last quarter. Institutional investors and hedge funds own 5.64% of the company’s stock.
A number of research analysts have issued reports on BNGO shares. Oppenheimer reiterated a “buy” rating on shares of Bionano Genomics in a research note on Wednesday, March 24th. Zacks Investment Research cut Bionano Genomics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Maxim Group lifted their price objective on Bionano Genomics from $2.00 to $14.00 in a research note on Friday, January 22nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $8.10.
Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings results on Monday, March 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). Bionano Genomics had a negative return on equity of 749.14% and a negative net margin of 510.42%. As a group, analysts anticipate that Bionano Genomics, Inc. will post -0.43 earnings per share for the current year.
Bionano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Story: What is a Stop Order?
Want to see what other hedge funds are holding BNGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bionano Genomics, Inc. (NASDAQ:BNGO).
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.